Gsa Capital Partners LLP Tcr2 Therapeutics Inc. Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$1.0 - $1.62 $37,452 - $60,672	37,452 New	37,452 $56,000
Q2 2022 Aug 09, 2022	SELL	$2.11 - $2.94 $334,631 - $466,263	-158,593 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$2.4 - $4.71 $202,058 - $396,539	84,191 Added 113.16%	158,593 $438,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $3,769 - $6,863	823 Added 1.12%	74,402 $347,000
Q3 2021 Nov 12, 2021	BUY	$8.44 - $18.35 $351,416 - $764,038	41,637 Added 130.35%	73,579 $626,000
Q2 2021 Aug 05, 2021	BUY	$16.41 - $24.71 $359,657 - $541,569	21,917 Added 218.62%	31,942 $524,000
Q1 2021 May 10, 2021	BUY	$20.38 - $34.07 $65,970 - $110,284	3,237 Added 47.69%	10,025 $221,000
Q4 2020 Feb 03, 2021	BUY	$19.0 - $32.63 $128,972 - $221,492	6,788 New	6,788 $210,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.